# US 2025/0164509 A1 · Methods and related aspects for detecting and quantifying amounts of n-terminal prohormone b-type natriuretic peptide in whole blood samples

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164509 A1
- Document ID: US20250164509A1
- Status: Published application
- Kind: A1
- Application number: 18/949,000
- Filed: 2024-11-15
- Published: 2025-05-22
- Earliest claimed: 2023-11-17
- Assignees: Arizona Board of Regents on behalf of Arizona State University
- Applicants: Arizona Board of Regents On Behalf of Arizona State University
- Inventors: Shaopeng WANG; Chao CHEN
- Web page: https://patentgrep.com/patent/US20250164509A1

## CPC

- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- B01L 3/502761: {specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads or physically stretching molecules}
- G01N 33/54346: {Nanoparticles}
- G01N 33/54386: {Analytical elements}
- B01L 2200/0647: Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L 2200/16: Reagents, handling or storing thereof
- B01L 2300/0654: Lenses; Optical fibres
- B01L 2300/0681: Filter
- G01N 2333/58: Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
- G01N 2470/04: Sandwich assay format
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- B01L: CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE

## Abstract

Provided herein are methods of quantifying amounts of N-terminal prohormone B-type natriuretic peptide (NT-proBNP) in whole blood samples. The methods include contacting detection antibody-NT-proBNP complexes with a plurality of capture antibodies, or antigen binding portions thereof, that specifically bind to the NT-proBNP molecules of the detection antibody-NT-proBNP complexes to form captured NT-proBNP complexes, and contacting NPs that each comprise a second recognition moiety that binds to the first recognition moiety of the detection antibodies, or antigen binding portions thereof, of the captured NT-proBNP complexes to form captured NP-NT-proBNP complexes. The methods also include taking images of the captured NP-NT-proBNP complexes to produce imaged captured NP-NT-proBNP complexes using a detection mechanism, and quantifying an amount of NT-proBNP in the sample aliquots using the imaged captured NP-NT-proBNP complexes. Additional methods as well as related devices and systems are also provided.

## Claims

### Claim 1

A method of quantifying an amount of N-terminal prohormone B-type natriuretic peptide (NT-proBNP) in a whole blood sample, comprising:
contacting detection antibody-NT-proBNP complexes with a plurality of capture antibodies, or antigen binding portions thereof, that specifically bind to the NT-proBNP molecules of the detection antibody-NT-proBNP complexes to form captured NT-proBNP complexes, wherein the detection antibody-NT-proBNP complexes were formed by contacting a substantially unprocessed NT-proBNP molecule-containing whole blood sample aliquot with a plurality of detection antibodies, or antigen binding portions thereof, that each comprise a first recognition moiety, which detection antibodies, or antigen binding portions thereof, specifically bind to the NT-proBNP molecules in the substantially unprocessed NT-proBNP molecule-containing whole blood sample aliquot to form the detection antibody-NT-proBNP complexes;
contacting nanoparticles (NPs) that each comprise a second recognition moiety that binds to the first recognition moiety of the detection antibodies, or antigen binding portions thereof, of the captured NT-proBNP complexes to form captured NP-NT-proBNP complexes;
taking images of the captured NP-NT-proBNP complexes to produce imaged captured NP-NT-proBNP complexes using a detection mechanism; and,
quantifying an amount of NT-proBNP in the sample aliquots using the imaged captured NP-NT-proBNP complexes, thereby quantifying the amount of NT-proBNP in the whole blood sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the detection antibodies, or antigen binding portions thereof, specifically bind to a first epitope of the NT-proBNP molecules, wherein the capture antibodies, or antigen binding portions thereof, specifically bind to a first epitope of the NT-proBNP molecules, and wherein the first and second epitopes differ from one another.

### Claim 3 (depends on 1)

The method of claim 1, wherein the captured NP-NT-proBNP complexes each comprise a single bound NP.

### Claim 4 (depends on 1)

The method of claim 1, wherein the quantifying step comprises digitally counting the imaged captured NP-NT-proBNP complexes in the images to quantify the amount of NT-proBNP in the whole blood sample.

### Claim 5 (depends on 1)

The method of claim 1, wherein the quantifying step comprises determining a concentration of the NT-proBNP in the whole blood sample.

### Claim 6 (depends on 1)

The method of claim 1, wherein the first recognition moiety is a compound selected from the group consisting of: biotin, streptavidin, avidin, an antibody, an antigen, an aptamer, a protein, a peptide, and a carbohydrate.

### Claim 7 (depends on 1)

The method of claim 1, wherein the second recognition moiety is a compound selected from the group consisting of: biotin, streptavidin, avidin, an antibody, an antigen, an aptamer, a protein, a peptide, and a carbohydrate.

### Claim 8 (depends on 1)

The method of claim 1, comprising flowing the detection antibody-NT-proBNP complexes through a plasma separator prior to contacting the detection antibody-NT-proBNP complexes with the plurality of capture antibodies, or antigen binding portions thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein the plurality of capture antibodies, or antigen binding portions thereof, are disposed on a surface of a solid support.

### Claim 10 (depends on 1)

The method of claim 1, comprising performing at least a portion of the method in a microfluidic digital nanobiosensor (mDNB) device or system.

### Claim 11 (depends on 1)

The method of claim 1, comprising obtaining the whole blood sample from a subject.

### Claim 12 (depends on 11)

The method of claim 11, comprising administering, or discontinuing administering, therapy to the subject based at least in part on the amount of NT-proBNP in the whole blood sample obtained from the subject.

### Claim 13 (depends on 11)

The method of claim 11, comprising generating a therapy recommendation for the subject based at least in part on the amount of NT-proBNP in the whole blood sample obtained from the subject.

### Claim 14

A microfluidic digital nanobiosensor (mDNB) device, comprising:
a body structure comprising at least one microfluidic channel disposed at least partially in the body structure;
a sample inlet area disposed at least partially in the body structure and in fluid communication with the microfluidic channel, wherein the sample inlet area is configured to receive sample aliquots that comprise mixtures of substantially unprocessed N-terminal prohormone B-type natriuretic peptide (NT-proBNP) molecule-containing whole blood and a plurality of detection antibodies, or antigen binding portions thereof, that each comprise a first recognition moiety, which detection antibodies, or antigen binding portions thereof, specifically bind to the NT-proBNP molecules in the whole blood to form detection antibody-NT-proBNP complexes;
an assay area disposed at least partially in the body structure and in fluid communication with the microfluidic channel;
a plasma separator disposed in the microfluidic channel between the sample inlet area and the assay area;
a plurality of capture antibodies, or antigen binding portions thereof, disposed on a surface of the assay area, wherein the capture antibodies, or antigen binding portions thereof, specifically bind to the NT-proBNP molecules of the detection antibody-NT-proBNP complexes when the detection antibody-NT-proBNP complexes are conveyed from the sample inlet area to the assay area through at least a portion of the microfluidic channel through the plasma separator into contact with the plurality of capture antibodies, or antigen binding portions thereof, to form captured NT-proBNP complexes; and,
a nanoparticle (NP) reservoir disposed at least partially in the body structure and in fluid communication with the microfluidic channel, which NP reservoir is configured to contain NPs that each comprise a second recognition moiety that binds to the first recognition moiety of the detection antibodies, or antigen binding portions thereof, of the captured NT-proBNP complexes when the NPs are conveyed from the NP reservoir to the assay area through at least a portion of the microfluidic channel into contact with the captured NT-proBNP complexes to form captured NP-NT-proBNP complexes;
wherein the mDNB device is configured to operably connect to a fluid conveyance mechanism that effects fluid conveyance through the microfluidic channel to and/or from the sample inlet area, the assay area, and the NP reservoir; and
wherein the mDNB device is configured to operably interface with a detection mechanism that images the captured NP-NT-proBNP complexes in the assay area to produce imaged captured NP-NT-proBNP complexes such that a controller operably connected to the detection mechanism quantifies an amount of NT-proBNP in the sample aliquots from the imaged captured NP-NT-proBNP complexes.

### Claim 15 (depends on 14)

The mDNB device of claim 14, wherein the detection antibodies, or antigen binding portions thereof, specifically bind to a first epitope of the NT-proBNP molecules, wherein the capture antibodies, or antigen binding portions thereof, specifically bind to a first epitope of the NT-proBNP molecules, and wherein the first and second epitopes differ from one another.

### Claim 16 (depends on 14)

The mDNB device of claim 14, wherein the captured NP-NT-proBNP complexes each comprise a single bound NP.

### Claim 17 (depends on 14)

The mDNB device of claim 14, wherein the controller comprises a processor, and a memory communicatively coupled to the processor, the memory storing non-transitory computer executable instructions which, when executed on the processor, perform operations comprising: digitally counting the imaged captured NP-NT-proBNP complexes in the images to quantify the amount of NT-proBNP in the sample aliquots.

### Claim 18 (depends on 14)

The mDNB device of claim 14, wherein the amount of NT-proBNP in the sample aliquots comprises a concentration of the NT-proBNP in the sample aliquots.

### Claim 19 (depends on 14)

The mDNB device of claim 14, wherein the detection mechanism comprises a bright-field microscope.

### Claim 20 (depends on 14)

The mDNB device of claim 14, wherein the NPs comprise metallic nanoparticles (MNPs).

### Claim 21 (depends on 14)

A kit comprising the mDNB device of claim 14.

### Claim 22 (depends on 14)

The mDNB device of claim 14, wherein the sample inlet area comprises a sample inlet port.

### Claim 23 (depends on 14)

The mDNB device of claim 14, wherein a microfluidic chip or cartridge comprises the mDNB device.

### Claim 24 (depends on 14)

The mDNB device of claim 14, wherein a point-of-care device comprises or is configured to receive the mDNB device.

### Claim 25 (depends on 14)

The mDNB device of claim 14, wherein the first recognition moiety is a compound selected from the group consisting of: biotin, streptavidin, avidin, an antibody, an antigen, an aptamer, a protein, a peptide, and a carbohydrate.

### Claim 26 (depends on 14)

The mDNB device of claim 14, wherein the second recognition moiety is a compound selected from the group consisting of: biotin, streptavidin, avidin, an antibody, an antigen, an aptamer, a protein, a peptide, and a carbohydrate.

### Claim 27

A microfluidic digital nanobiosensor (mDNB) system, comprising:
a mDNB device receiving area structured to receive at least one mDNB device that comprises:
a body structure comprising at least one microfluidic channel disposed at least partially in the body structure;
a sample inlet area disposed at least partially in the body structure and in fluid communication with the microfluidic channel, wherein the sample inlet area is configured to receive sample aliquots that comprise mixtures of substantially unprocessed N-terminal prohormone B-type natriuretic peptide (NT-proBNP) molecule-containing whole blood and a plurality of detection antibodies, or antigen binding portions thereof, that each comprise a first recognition moiety, which detection antibodies, or antigen binding portions thereof, specifically bind to the NT-proBNP molecules in the whole blood to form detection antibody-NT-proBNP complexes;
an assay area disposed at least partially in the body structure and in fluid communication with the microfluidic channel;
a plasma separator disposed in the microfluidic channel between the sample inlet area and the assay area;
a plurality of capture antibodies, or antigen binding portions thereof, disposed on a surface of the assay area, wherein the capture antibodies, or antigen binding portions thereof, specifically bind to the NT-proBNP molecules of the detection antibody-NT-proBNP complexes when the detection antibody-NT-proBNP complexes are conveyed from the sample inlet area to the assay area through at least a portion of the microfluidic channel through the plasma separator into contact with the plurality of capture antibodies, or antigen binding portions thereof, to form captured NT-proBNP complexes; and,
a nanoparticle (NP) reservoir disposed at least partially in the body structure and in fluid communication with the microfluidic channel, which NP reservoir is configured to contain NPs that each comprise a second recognition moiety that binds to the first recognition moiety of the detection antibodies, or antigen binding portions thereof, of the captured NT-proBNP complexes when the NPs are conveyed from the NP reservoir to the assay area through at least a portion of the microfluidic channel into contact with the captured NT-proBNP complexes to form captured NP-NT-proBNP complexes;
a fluid conveyance mechanism that operably connects to the mDNB device when the mDNB device is received in the mDNB device receiving area, which fluid conveyance mechanism is configured to effect fluid conveyance through the microfluidic channel to and/or from the sample inlet area, the assay area, and the NP reservoir;
a detection mechanism that is configured to take images of the captured NP-NT-proBNP complexes in the assay area to produce imaged captured NP-NT-proBNP complexes when the mDNB device is received in the mDNB device receiving area; and,
a controller comprises a processor, and a memory communicatively directly or remotely coupled to the processor, the memory storing non-transitory computer executable instructions which, when executed on the processor, perform operations comprising:
conveying the fluid through the microfluidic channel to and/or from the sample inlet area, the assay area, and the NP reservoir using the fluid conveyance mechanism;
taking the images of the captured NP-NT-proBNP complexes in the assay area to produce the imaged captured NP-NT-proBNP complexes using the detection mechanism; and
quantifying an amount of NT-proBNP in the sample aliquots using the imaged captured NP-NT-proBNP complexes.

### Claim 28 (depends on 27)

The mDNB system of claim 27, wherein the detection antibodies, or antigen binding portions thereof, specifically bind to a first epitope of the NT-proBNP molecules, wherein the capture antibodies, or antigen binding portions thereof, specifically bind to a first epitope of the NT-proBNP molecules, and wherein the first and second epitopes differ from one another.

### Claim 29 (depends on 27)

The mDNB system of claim 27, wherein the captured NP-NT-proBNP complexes each comprise a single bound NP.

### Claim 30 (depends on 27)

The mDNB system of claim 27, wherein the amount of NT-proBNP in the sample aliquots comprises a concentration of the NT-proBNP in the sample aliquots.

### Claim 31 (depends on 27)

The mDNB system of claim 27, wherein the detection mechanism comprises a bright-field microscope.

### Claim 32 (depends on 27)

The mDNB system of claim 27, wherein the NPs comprise metallic nanoparticles (MNPs).

### Claim 33 (depends on 27)

The mDNB system of claim 27, wherein a microfluidic chip or cartridge comprises the mDNB device.

### Claim 34 (depends on 27)

The mDNB system of claim 27, wherein the system comprises a point-of-care device that comprises or is configured to receive the mDNB device.

### Claim 35 (depends on 27)

The mDNB system of claim 27, wherein the first recognition moiety is a compound selected from the group consisting of: biotin, streptavidin, avidin, an antibody, an antigen, an aptamer, a protein, a peptide, and a carbohydrate.

### Claim 36 (depends on 27)

The mDNB system of claim 27, wherein the second recognition moiety is a compound selected from the group consisting of: biotin, streptavidin, avidin, an antibody, an antigen, an aptamer, a protein, a peptide, and a carbohydrate.

### Claim 37 (depends on 27)

The mDNB system of claim 27, wherein the mDNB system is configured to detect the NT-proBNP molecules in a range of about 1-10,000 pg/mL from less than about 10 μL of a given whole blood sample in about 15 minutes or less.
